¾È³çÇϽʴϱî?
±¹°¡ÁöÁ¤ ÀÇÇבּ¸Á¤º¸¼¾ÅÍ¿Í ¾Æ½Ã¾ÆÅÂÆò¾çÃÊ°í¼Ó¿¬±¸¸Á, ±¹¸³¾Ï¼¾ÅÍ¿¡¼´Â Á¤º¸È½Ã´ë ÀÇÇבּ¸¼¼¹Ì³ªÀÇ ±¹Á¦±³·ù È°¼ºÈ¸¦ À§Çؼ ±¹Á¦¼¼¹Ì³ª¸¦ ±¹³» ÃÖÃÊ·Î ½º¸¶Æ®ÆùÀ¸·Î ½Ç½Ã°£ Á߰踦 ÇϰԵǾú½À´Ï´Ù.
½Ã°£Ç¥¸¦ º¸½Ã°í ÇØ´ç ½Ã°£¿¡ ½º¸¶Æ®ÆùÀ¸·Î ¸¹Àº ½Ãû¹Ù¶ø´Ï´Ù.
2011. 8. 22. ±¹°¡ÁöÁ¤ ÀÇÇבּ¸Á¤º¸¼¾ÅÍ ¿Ã¸².
³ª³ë ±â¼úÀº ¾ÏÀÇ Áø´Ü ¹× Ä¡·á ºÐ¾ß¿¡ ÀÖ¾î¼ ±âÁ¸ÀÇ ¹æ½ÄÀ» ȹ±âÀûÀ¸·Î ¹Ù²Ü ¼ö ÀÖ´Â °·ÂÇÑ °¡´É¼ºÀ» º¸¿© ÁÖ°í ÀÖ´Ù. ÃÖ½ÅÀÇ ±×¸®°í ´Ù±â´ÉÀ» °®Ãá ³ª³ë ÀǾàÇ° µéÀº ¾ÏÀ» Ãʱ⠴ܰ迡¼ Áø´ÜÇÒ ¼ö ÀÖµµ·Ï ÇØÁÖ°í, ¸ö ¼Ó¿¡ Á¸ÀçÇÏ´Â ¾ÏÀÇ À§Ä¡¸¦ ²À Âó¾î¼ Á¤È®È÷ º¸¿©ÁÙ ¼ö ÀÖÀ» »Ó ¾Æ´Ï¶ó ¾î¶°ÇÑ Ç×¾ÏÁ¦¿¡ Àß ¹ÝÀÀÇÒ °ÍÀÎÁö¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇÑ´Ù. ¶ÇÇÑ, Ç×¾ÏÁ¦¸¦ ¾Ï Á¶Á÷¿¡¸¸ ƯÀÌÀûÀ¸·Î Àü´ÞÇÔÀ¸·Î½á ±âÁ¸ÀÇ Ç×¾ÏÁ¦°¡ Á¤»ó Á¶Á÷¿¡µµ ÃàÀûµÇ´Â °Í¿¡ ÀÇÇؼ ³ªÅ¸³µ´ø ½É°¢ÇÑ ¾à¹° ºÎÀÛ¿ëÀ» ȹ±âÀûÀ¸·Î ÁÙÀÏ ¼ö ÀÖ°í, Ç×¾ÏÁ¦ ³»¼ºÀ» º¸ÀÌ´Â ¾ÏÀÇ Ä¡·á¿¡µµ È¿°ú°¡ ÀÖ´Ù´Â °ÍÀ» º¸¿© ¿Ô´Ù. ÃÖ±Ù¿¡ °³¹ßµÇ°í ÀÖ´Â »ýü ¹ÙÀÌ¿À ¼¾¼µéÀº ±âÁ¸ÀÇ ±â¼ú·Î´Â °ËÃâÇØ ³»Áö ¸øÇß´ø ¾ÆÁÖ ÀÛÀº Á¾¾ç µé ¹× ÀüÀÌ ¾Ï ¼¼Æ÷µéÀÇ Á¸Àç ¹× À§Ä¡¸¦ Áø´ÜÇØ ³¾ ¼ö ÀÖÀ» »Ó ¾Æ´Ï¶ó, ȯÀÚ¿¡°Ô Åõ¿©µÈ Ä¡·áÁ¦Á¦°¡ Ç¥ÀûÀ¸·Î ÇÏ´Â ¾Ï¼¼Æ÷ ³» ºÐÀÚ¿¡ ½ÇÁ¦·Î ÀÛ¿ëÀ» ÇÏ°í ÀÖ´ÂÁö¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸¸¦ ¿µ»óÀ¸·Î Á¦°øÇØ ÁÜÀ¸·Î½á ¾Ï ÀÇ Áø´Ü ¹× Ä¡·á¿¡ Ä¿´Ù¶õ º¯È¸¦ ÀÏÀ¸Å³ °ÍÀ¸·Î ¿¹»óµÈ´Ù.
¾ÏÀÇ Áø´Ü ¹× Ä¡·á¿¡ ÀÖ¾î¼ÀÇ ÀÌ·¯ÇÑ ³ª³ë ÀǾàÇ°ÀÇ ¹«ÇÑÇÑ °¡´É¼º¿¡ µû¶ó¼, NCI´Â Alliance for Nanotechnology in Cancer ÇÁ·Î±×·¥À» 2004³âºÎÅÍ °³½ÃÇÏ¿´À¸¸ç, ¾ÏÀÇ Áø´Ü,Ä¡·á, ¿¹¹æÀ» À§ÇÏ¿© 5³â¿¡ °ÉÃļ ¾à 1¾ï 5õ¸¸ºÒ¿¡ À̸£´Â ¸·´ëÇÑ ¿¬±¸ºñ¸¦ Áö¿øÇØ ¿À°í ÀÖ´Ù. ÇöÀç ¹Ì±¹¿¡´Â MIT-Harvard Center of Cancer Nanotechnology Excellence¸¦ Æ÷ÇÔÇÏ¿© 9°³ÀÇ ¶Ù¾î³ ¾Ï ³ª³ë±â¼ú ¼¾ÅÍ°¡ Á¸ÀçÇϸç, ÀÌ·¯ÇÑ ³ª³ë¼¾Å͵éÀº »õ·Î¿î ³ª³ë±â¼ú °³¹ß°ú À̵éÀÇ ½ÇÁ¦ ÀÓ»ó Àû¿ë¿¡ °üÇÑ ¿¬±¸¿¡ ÁßÃßÀûÀÎ ¿ªÇÒÀ» ¼öÇàÇÏ°í ÀÖ´Ù.
º» ºñµð¿À ½ÉÆ÷Áö¿ò¿¡¼´Â NCI Alliance for nanotechnology in Cancer µð·ºÅÍÀÎ Piotro Grodzinski ¹Ú»çÀÇ ³ª³ë ±â¼ú°ú ±âȸ ¹ßÇ¥¿Í, UCLA ÈÇаúÀÇ ¼®Á±³¼öÀÎ Jeffrey I Zink ¹Ú»çÀÇ ´Ù±â´É¼º ½Ç¸®Ä« ³ª³ëÀÔÀÚ¸¦ ÀÌ¿ëÇÑ ¾Ï Áø´Ü ¹× Ä¡·á ¿¬±¸¸¦ Æ÷ÇÔÇÏ¿©, ¾ÏÀÇ Áø´Ü, Ä¡·á, ¿¹¹æ¿¡ ÀÖ¾î¼ ³ª³ë ±â¼úÀÇ ¹«ÇÑÇÑ °¡´É¼º°ú ÀÌ·¯ÇÑ ³ª³ë ±â¼úµéÀ» ¾ÏȯÀÚ¿¡°Ô Àû¿ëÇϱâ À§Çؼ ¿ì¸®°¡ ±Øº¹ÇØ¾ß µÉ ¹®Á¦Á¡µé¿¡ ´ëÇؼ, ³ª³ë±â¼úÀ» ¼±µµÇÏ°í ÀÖ´Â ¹Ì±¹±¹¸³¾Ï¼¾ÅÍ, ¹Ì±¹ Ä̸®Æ÷´Ï¾Æ ³ª³ë½Ã½ºÅÛ ¿¬±¸¼Ò, Áß±¹ ³ª³ë°úÇÐ ±â¼ú ±¹¸³ ¿¬±¸¼¾ÅÍ, Çѱ¹ ±¹¸³¾Ï¼¾ÅÍÀÇ ¿¬±¸ÀÚµéÀÌ ¸ð¿©¼ Åä·ÐÇÏ°Ô µÈ´Ù.
Program of Healthcare session-1: International Collaborative Research on Cancer and Nanotechnology
Date: 7:00-10:30, August 24 IST
India |
7:00–10:30, August 24 |
China |
9:30-13:00, August 24 |
Korea |
10:30-14:00, August 24 |
LA, USA |
18:30-22:00, August 23 |
Bethesda, USA |
21:30, August 23 – 01:00, August 24 |
Organizers: YoungSung Lee, Ed Johansen
Chairperson: YoungSung Lee
USA moderator: Fuyu Tamanoi
Korea moderator: Yongdoo Choi
System: Polycom and its compatibles
Engineers in charge: Juyong Lee, Byoung-Ki Koo
Local engineer:Ti-Chuang Chiang
Connecting stations
1. APAN Meeting Room (New Delhi)
Network engineer: Ti-Chuang Chiang
2. NCC (Ilsan, Korea)
Network engineer: Juyong Lee, Byoung-Ki Koo
3. NCI (Bethesda, USA)
Network engineer: Todd Cox
4. NCI (Fredericks, USA)
Network engineer: Todd Cox
5. UCLA(LA, USA)
Network engineer: Noushig Karpanian
6. NCNST (Beijing, China)
Network engineer: Dongliang Wang
Session 1-a
Time: 7:00-7:30 IST
Speakers
1.Jin-Soo Lee (NCC, Korea)
2.Judith C. Gasson (UCLA, USA)
3.Piotr Grodzinski (NCI, USA): ¡°Cancer Nanotechnology – Opportunities and Challenges – View from the NCI Alliance for Nanotechnology in Cancer¡±
Session 1-b
Time: 7:30-9:00 IST
Speakers
1.Anil K. Patri (NCI, USA): ¡°Resources for Preclinical Assessment of Nanomaterials¡±
2.Jacob Berlin (City of Hope, Duarte, USA): ¡°Carbon-based Nanovectors for targeted paclitaxel delivery¡±
3. Jose Galvez (NCI, USA): ¡°International Cancer Research Programs¡±
4. Jeffrey I. Zink (UCLA, USA): ¡°Multifunctional Mesoporous Nanoparticles for Targeting, Imaging and Drug Delivery¡±
5. Hsian-Rong Tseng(UCLA, USA): "Nano-velcro for Identification and Isolation of Circulating Tumor cells from Whole Blood"
6. Fuyu Tamanoi (UCLA, USA): ¡°Anti-tumor Efficacy of Camptothecin-loaded Mesoporous Nanoparticles¡±
Break: 9:00-9:10 IST
Session 1-c
Time: 9:10-10:30 IST
Speakers
1. Xingyu Jiang (NCNST, Beijing, China): ¡°What nanoparticles could do to improve the quality of in vitro diagnostic assays?¡±
2. Xing-Jie Liang (NCNST, Beijing, China): ¡°Unique Biological and Medical Effects of Structures with Nanoscale Characterizations¡±
3. Amit Dinda (All Institute of Medical Sciences, New Delhi, India): ¡°Cancer cell targeting with nanoparticle for drug delivery; The therapeutic and safety issues¡±
4. Sangyong Jon (Gwangju Institute of Science and Technology, Korea): ¡°Aptide-based Nanomedicine for Cancer Imaging and Therapy¡±
5. Ji Ho Park (Korea Advanced Institute of Science and Technology, Korea): ¡°A Systems Approach to Engineering Cancer Nanotechnologies¡±